1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsExpanding the Target Landscape by Drugging the Undruggable (R21 Clinical Trial Not Allowed) is sponsored by National Institutes of Health. This opportunity supports mission-aligned projects and measurable outcomes.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Expanding the Target Landscape by Drugging the Undruggable (R21 Clinical Trial Not Allowed) Department of Health and Human Services National Institutes of Health Document Type:Grants Notice Funding Opportunity Number:PAR-25-442 Funding Opportunity Title:Expanding the Target Landscape by Drugging the Undruggable (R21 Clinical Trial Not Allowed) Opportunity Category:Discretionary Opportunity Category Explanation: Funding Instrument Type:Grant Category of Funding Activity:Health Expected Number of Awards: Assistance Listings:93.
121 -- Oral Diseases and Disorders Research 93. 242 -- Mental Health Research Grants 93. 350 -- National Center for Advancing Translational Sciences 93.
855 -- Allergy and Infectious Diseases Research 93. 865 -- Child Health and Human Development Extramural Research 93.
867 -- Vision Research Cost Sharing or Matching Requirement:No Last Updated Date:Jul 29, 2025 Original Closing Date for Applications:Feb 17, 2028 Current Closing Date for Applications:Feb 17, 2028 Archive Date:Mar 24, 2028 Estimated Total Program Funding: Eligible Applicants:Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments Private institutions of higher education Others (see text field entitled "Additional Information on Eligibility" for clarification) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Native American tribal governments (Federally recognized) City or township governments Public and State controlled institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Independent school districts Public housing authorities/Indian housing authorities Additional Information on Eligibility:Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
## Additional Information Agency Name:National Institutes of Health Description:The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications for exploratory and early-stage projects that focus on undruggable target classes within intractable human disease.
Applicants will identify a human disease relevant undruggable target class and develop a method or agent that is selective for one or more targets within that target class. This NOFO is intended to jumpstart research that demonstrates innovative strategies to modulate targets that cannot be addressed by established therapeutic types, furthering the development of methods and/or agents selective for undruggable target classes.
Link to Additional Information:https://grants. nih. gov/grants/guide/pa-files/PAR-25-442.
html Grantor Contact Information:If you have difficulty accessing the full announcement electronically, please contact: ## Similar Opportunities (identified by AI)
According to the current listing, eligibility includes: Eligible applicants: State governments; County governments; City or township governments; Special district governments; Independent school districts; Public and State controlled institutions of higher education; Native …. Confirm the full requirements in the official notice before applying.
Applications for Expanding the Target Landscape by Drugging the Undruggable (R21 Clinical Trial Not Allowed) are due February 17, 2028. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Yes — Expanding the Target Landscape by Drugging the Undruggable (R21 Clinical Trial Not Allowed) is offered by National Institutes of Health and this listing comes from Grants.gov, an official U.S. federal source. Federal applications generally require registrations (for example SAM.gov or an agency submission portal), so allow extra lead time.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article